Antinuclear antibody testing.
The ANA test is an excellent screening test for patients with SLE and a few other connective tissue diseases. The LE cell preparation is an assay that is subjective and costly. Because of the presence of a superior screening test (the ANA) and superior specific auto-antibody tests, the author recommends that the use of LE cell preparations be discontinued. ANA screening tests may be performed either by indirect microscopic serology (usually IFA) or EIA. The latter technique is readily automated and many new products for this screening test have appeared in the past decade. The products differ, however, and laboratories are cautioned to test each in the context of the clinical needs of their clinicians. Proper use of the ANA test requires each laboratory to determine the cutoff used under their conditions of assay. Although either ANA screening test has a high negative predictive value in numerous studies, proper selection of patients to be tested is key to improving the predictive value of a positive result. The American College of Rheumatism criteria are reviewed and recommended as part of the patient selection process for this testing.
Warde Medical Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48108, USA. dfkeren@yahoo.com
David F
DF
Keren
D000974:Antibodies, Antinuclear / Q000097:blood*; D001327:Autoimmune Diseases / Q000097:blood / Q000175:diagnosis*; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007124:Immunoenzyme Techniques; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis*; D010338:Pathology, Clinical / Q000379:methods*; D011237:Predictive Value of Tests; D012372:ROC Curve
D000974:Antibodies, Antinuclear